Global Pulmonary Hypertension Drug Market Insights and Forecast to 2026

Publisher Name :
Date: 01-Jul-2020
No. of pages: 110
Inquire Before Buying

Pulmonary Hypertension Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Hypertension Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Pulmonary Hypertension Drug market is segmented into

- IK-3001

- Sildenafil Citrate IMD

- IK-7002

- Riociguat

- SAR-407899

- Others

Segment by Application, the Pulmonary Hypertension Drug market is segmented into

- Clinic

- Hospital

- Others

Regional and Country-level Analysis

The Pulmonary Hypertension Drug market is analysed and market size information is provided by regions (countries).

The key regions covered in the Pulmonary Hypertension Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Pulmonary Hypertension Drug Market Share Analysis

Pulmonary Hypertension Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Pulmonary Hypertension Drug business, the date to enter into the Pulmonary Hypertension Drug market, Pulmonary Hypertension Drug product introduction, recent developments, etc.

The major vendors covered:

- Sanofi

- Vectura Group plc

- Bayer AG

- Ikaria Inc.

- Proreo Pharma AG

- Vicore Pharma AB

- Biolab Sanus Farmaceutica Ltda.

- Hanmi Pharmaceuticals, Co. Ltd.

Global Pulmonary Hypertension Drug Market Insights and Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Pulmonary Hypertension Drug Product Introduction
1.2 Market Segments
1.3 Key Pulmonary Hypertension Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Type
1.4.2 IK-3001
1.4.3 Sildenafil Citrate IMD
1.4.4 IK-7002
1.4.5 Riociguat
1.4.6 SAR-407899
1.4.7 Others
1.5 Market by Application
1.5.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Pulmonary Hypertension Drug Market Size, Estimates and Forecasts
2.1.1 Global Pulmonary Hypertension Drug Revenue 2015-2026
2.1.2 Global Pulmonary Hypertension Drug Sales 2015-2026
2.2 Global Pulmonary Hypertension Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Pulmonary Hypertension Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Pulmonary Hypertension Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Pulmonary Hypertension Drug Competitor Landscape by Players
3.1 Pulmonary Hypertension Drug Sales by Manufacturers
3.1.1 Pulmonary Hypertension Drug Sales by Manufacturers (2015-2020)
3.1.2 Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Pulmonary Hypertension Drug Revenue by Manufacturers
3.2.1 Pulmonary Hypertension Drug Revenue by Manufacturers (2015-2020)
3.2.2 Pulmonary Hypertension Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Pulmonary Hypertension Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Pulmonary Hypertension Drug Revenue in 2019
3.2.5 Global Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Pulmonary Hypertension Drug Price by Manufacturers
3.4 Pulmonary Hypertension Drug Manufacturing Base Distribution, Product Types
3.4.1 Pulmonary Hypertension Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Pulmonary Hypertension Drug Product Type
3.4.3 Date of International Manufacturers Enter into Pulmonary Hypertension Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Pulmonary Hypertension Drug Market Size by Type (2015-2020)
4.1.1 Global Pulmonary Hypertension Drug Sales by Type (2015-2020)
4.1.2 Global Pulmonary Hypertension Drug Revenue by Type (2015-2020)
4.1.3 Pulmonary Hypertension Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Pulmonary Hypertension Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Pulmonary Hypertension Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Pulmonary Hypertension Drug Revenue Forecast by Type (2021-2026)
4.2.3 Pulmonary Hypertension Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Pulmonary Hypertension Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Pulmonary Hypertension Drug Market Size by Application (2015-2020)
5.1.1 Global Pulmonary Hypertension Drug Sales by Application (2015-2020)
5.1.2 Global Pulmonary Hypertension Drug Revenue by Application (2015-2020)
5.1.3 Pulmonary Hypertension Drug Price by Application (2015-2020)
5.2 Pulmonary Hypertension Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Pulmonary Hypertension Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Pulmonary Hypertension Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Pulmonary Hypertension Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Pulmonary Hypertension Drug by Country
6.1.1 North America Pulmonary Hypertension Drug Sales by Country
6.1.2 North America Pulmonary Hypertension Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Pulmonary Hypertension Drug Market Facts & Figures by Type
6.3 North America Pulmonary Hypertension Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Pulmonary Hypertension Drug by Country
7.1.1 Europe Pulmonary Hypertension Drug Sales by Country
7.1.2 Europe Pulmonary Hypertension Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Pulmonary Hypertension Drug Market Facts & Figures by Type
7.3 Europe Pulmonary Hypertension Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Pulmonary Hypertension Drug by Region
8.1.1 Asia Pacific Pulmonary Hypertension Drug Sales by Region
8.1.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Pulmonary Hypertension Drug Market Facts & Figures by Type
8.3 Asia Pacific Pulmonary Hypertension Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Pulmonary Hypertension Drug by Country
9.1.1 Latin America Pulmonary Hypertension Drug Sales by Country
9.1.2 Latin America Pulmonary Hypertension Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Pulmonary Hypertension Drug Market Facts & Figures by Type
9.3 Central & South America Pulmonary Hypertension Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Pulmonary Hypertension Drug by Country
10.1.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Country
10.1.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Pulmonary Hypertension Drug Market Facts & Figures by Type
10.3 Middle East and Africa Pulmonary Hypertension Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Description and Business Overview
11.1.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Sanofi Pulmonary Hypertension Drug Products Offered
11.1.5 Sanofi Related Developments
11.2 Vectura Group plc
11.2.1 Vectura Group plc Corporation Information
11.2.2 Vectura Group plc Description and Business Overview
11.2.3 Vectura Group plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Vectura Group plc Pulmonary Hypertension Drug Products Offered
11.2.5 Vectura Group plc Related Developments
11.3 Bayer AG
11.3.1 Bayer AG Corporation Information
11.3.2 Bayer AG Description and Business Overview
11.3.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bayer AG Pulmonary Hypertension Drug Products Offered
11.3.5 Bayer AG Related Developments
11.4 Ikaria Inc.
11.4.1 Ikaria Inc. Corporation Information
11.4.2 Ikaria Inc. Description and Business Overview
11.4.3 Ikaria Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Ikaria Inc. Pulmonary Hypertension Drug Products Offered
11.4.5 Ikaria Inc. Related Developments
11.5 Proreo Pharma AG
11.5.1 Proreo Pharma AG Corporation Information
11.5.2 Proreo Pharma AG Description and Business Overview
11.5.3 Proreo Pharma AG Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Products Offered
11.5.5 Proreo Pharma AG Related Developments
11.6 Vicore Pharma AB
11.6.1 Vicore Pharma AB Corporation Information
11.6.2 Vicore Pharma AB Description and Business Overview
11.6.3 Vicore Pharma AB Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Products Offered
11.6.5 Vicore Pharma AB Related Developments
11.7 Biolab Sanus Farmaceutica Ltda.
11.7.1 Biolab Sanus Farmaceutica Ltda. Corporation Information
11.7.2 Biolab Sanus Farmaceutica Ltda. Description and Business Overview
11.7.3 Biolab Sanus Farmaceutica Ltda. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Products Offered
11.7.5 Biolab Sanus Farmaceutica Ltda. Related Developments
11.8 Hanmi Pharmaceuticals, Co. Ltd.
11.8.1 Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
11.8.2 Hanmi Pharmaceuticals, Co. Ltd. Description and Business Overview
11.8.3 Hanmi Pharmaceuticals, Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Products Offered
11.8.5 Hanmi Pharmaceuticals, Co. Ltd. Related Developments
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Description and Business Overview
11.1.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Sanofi Pulmonary Hypertension Drug Products Offered
11.1.5 Sanofi Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Pulmonary Hypertension Drug Market Estimates and Projections by Region
12.1.1 Global Pulmonary Hypertension Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Pulmonary Hypertension Drug Revenue Forecast by Regions 2021-2026
12.2 North America Pulmonary Hypertension Drug Market Size Forecast (2021-2026)
12.2.1 North America: Pulmonary Hypertension Drug Sales Forecast (2021-2026)
12.2.2 North America: Pulmonary Hypertension Drug Revenue Forecast (2021-2026)
12.2.3 North America: Pulmonary Hypertension Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Pulmonary Hypertension Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Pulmonary Hypertension Drug Sales Forecast (2021-2026)
12.3.2 Europe: Pulmonary Hypertension Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Pulmonary Hypertension Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Pulmonary Hypertension Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Pulmonary Hypertension Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Pulmonary Hypertension Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Pulmonary Hypertension Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Pulmonary Hypertension Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Pulmonary Hypertension Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Pulmonary Hypertension Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Pulmonary Hypertension Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Pulmonary Hypertension Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Pulmonary Hypertension Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Pulmonary Hypertension Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Pulmonary Hypertension Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Pulmonary Hypertension Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Pulmonary Hypertension Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Pulmonary Hypertension Drug Market Segments
Table 2. Ranking of Global Top Pulmonary Hypertension Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Pulmonary Hypertension Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of IK-3001
Table 5. Major Manufacturers of Sildenafil Citrate IMD
Table 6. Major Manufacturers of IK-7002
Table 7. Major Manufacturers of Riociguat
Table 8. Major Manufacturers of SAR-407899
Table 9. Major Manufacturers of Others
Table 10. Global Pulmonary Hypertension Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Pulmonary Hypertension Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Pulmonary Hypertension Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Pulmonary Hypertension Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Pulmonary Hypertension Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Pulmonary Hypertension Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Pulmonary Hypertension Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Pulmonary Hypertension Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Pulmonary Hypertension Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Hypertension Drug as of 2019)
Table 19. Pulmonary Hypertension Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Pulmonary Hypertension Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Pulmonary Hypertension Drug Price (2015-2020) (USD/Pcs)
Table 22. Pulmonary Hypertension Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Pulmonary Hypertension Drug Product Type
Table 24. Date of International Manufacturers Enter into Pulmonary Hypertension Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Pulmonary Hypertension Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Pulmonary Hypertension Drug Sales Share by Type (2015-2020)
Table 28. Global Pulmonary Hypertension Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Pulmonary Hypertension Drug Revenue Share by Type (2015-2020)
Table 30. Pulmonary Hypertension Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Pulmonary Hypertension Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Pulmonary Hypertension Drug Sales Share by Application (2015-2020)
Table 33. North America Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 35. North America Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Pulmonary Hypertension Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 39. North America Pulmonary Hypertension Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Pulmonary Hypertension Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Pulmonary Hypertension Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Pulmonary Hypertension Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Pulmonary Hypertension Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Pulmonary Hypertension Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Pulmonary Hypertension Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Pulmonary Hypertension Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Pulmonary Hypertension Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Table 73. Sanofi Corporation Information
Table 74. Sanofi Description and Major Businesses
Table 75. Sanofi Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Sanofi Product
Table 77. Sanofi Recent Development
Table 78. Vectura Group plc Corporation Information
Table 79. Vectura Group plc Description and Major Businesses
Table 80. Vectura Group plc Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Vectura Group plc Product
Table 82. Vectura Group plc Recent Development
Table 83. Bayer AG Corporation Information
Table 84. Bayer AG Description and Major Businesses
Table 85. Bayer AG Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Bayer AG Product
Table 87. Bayer AG Recent Development
Table 88. Ikaria Inc. Corporation Information
Table 89. Ikaria Inc. Description and Major Businesses
Table 90. Ikaria Inc. Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Ikaria Inc. Product
Table 92. Ikaria Inc. Recent Development
Table 93. Proreo Pharma AG Corporation Information
Table 94. Proreo Pharma AG Description and Major Businesses
Table 95. Proreo Pharma AG Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Proreo Pharma AG Product
Table 97. Proreo Pharma AG Recent Development
Table 98. Vicore Pharma AB Corporation Information
Table 99. Vicore Pharma AB Description and Major Businesses
Table 100. Vicore Pharma AB Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Vicore Pharma AB Product
Table 102. Vicore Pharma AB Recent Development
Table 103. Biolab Sanus Farmaceutica Ltda. Corporation Information
Table 104. Biolab Sanus Farmaceutica Ltda. Description and Major Businesses
Table 105. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Biolab Sanus Farmaceutica Ltda. Product
Table 107. Biolab Sanus Farmaceutica Ltda. Recent Development
Table 108. Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
Table 109. Hanmi Pharmaceuticals, Co. Ltd. Description and Major Businesses
Table 110. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Hanmi Pharmaceuticals, Co. Ltd. Product
Table 112. Hanmi Pharmaceuticals, Co. Ltd. Recent Development
Table 113. Global Pulmonary Hypertension Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 114. Global Pulmonary Hypertension Drug Sales Market Share Forecast by Regions (2021-2026)
Table 115. Global Pulmonary Hypertension Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 116. Global Pulmonary Hypertension Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 117. North America: Pulmonary Hypertension Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 118. North America: Pulmonary Hypertension Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 119. Europe: Pulmonary Hypertension Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 120. Europe: Pulmonary Hypertension Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Asia Pacific: Pulmonary Hypertension Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 122. Asia Pacific: Pulmonary Hypertension Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 123. Latin America: Pulmonary Hypertension Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 124. Latin America: Pulmonary Hypertension Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 125. Middle East and Africa: Pulmonary Hypertension Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 126. Middle East and Africa: Pulmonary Hypertension Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 127. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 128. Key Challenges
Table 129. Market Risks
Table 130. Main Points Interviewed from Key Pulmonary Hypertension Drug Players
Table 131. Pulmonary Hypertension Drug Customers List
Table 132. Pulmonary Hypertension Drug Distributors List
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Hypertension Drug Product Picture
Figure 2. Global Pulmonary Hypertension Drug Sales Market Share by Type in 2020 & 2026
Figure 3. IK-3001 Product Picture
Figure 4. Sildenafil Citrate IMD Product Picture
Figure 5. IK-7002 Product Picture
Figure 6. Riociguat Product Picture
Figure 7. SAR-407899 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Pulmonary Hypertension Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Pulmonary Hypertension Drug Report Years Considered
Figure 14. Global Pulmonary Hypertension Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Pulmonary Hypertension Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Pulmonary Hypertension Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Pulmonary Hypertension Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Pulmonary Hypertension Drug Sales Market Share by Region in 2019
Figure 19. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Pulmonary Hypertension Drug Revenue Market Share by Region in 2019
Figure 21. Global Pulmonary Hypertension Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Pulmonary Hypertension Drug Revenue in 2019
Figure 23. Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 26. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Pulmonary Hypertension Drug Revenue Market Share by Type in 2019
Figure 28. Global Pulmonary Hypertension Drug Market Share by Price Range (2015-2020)
Figure 29. Global Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Pulmonary Hypertension Drug Sales Market Share by Application in 2019
Figure 31. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Pulmonary Hypertension Drug Revenue Market Share by Application in 2019
Figure 33. North America Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 36. North America Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Pulmonary Hypertension Drug Market Share by Type in 2019
Figure 42. North America Pulmonary Hypertension Drug Market Share by Application in 2019
Figure 43. Europe Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 46. Europe Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 47. Germany Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Pulmonary Hypertension Drug Market Share by Type in 2019
Figure 58. Europe Pulmonary Hypertension Drug Market Share by Application in 2019
Figure 59. Asia Pacific Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Pulmonary Hypertension Drug Revenue Market Share by Region in 2019
Figure 63. China Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Pulmonary Hypertension Drug Market Share by Type in 2019
Figure 86. Asia Pacific Pulmonary Hypertension Drug Market Share by Application in 2019
Figure 87. Latin America Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 90. Latin America Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Pulmonary Hypertension Drug Market Share by Type in 2019
Figure 98. Latin America Pulmonary Hypertension Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Pulmonary Hypertension Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Pulmonary Hypertension Drug Market Share by Application in 2019
Figure 111. North America Pulmonary Hypertension Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Pulmonary Hypertension Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Pulmonary Hypertension Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Pulmonary Hypertension Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Pulmonary Hypertension Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Pulmonary Hypertension Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Pulmonary Hypertension Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Pulmonary Hypertension Drug Revenue G
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs